Olmesartán Vir (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Vir, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It selectively blocks AT1 receptors, reducing vasoconstriction and aldosterone release, which helps lower elevated blood pressure in adults diagnosed with hypertension and lowers the risk of cardiovascular complications.

GNH USA supplies Olmesartán Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent product quality, regulatory compliance, and reliable global distribution to meet local market needs.

Olmesartán Vir, an angiotensin II receptor blocker, is used to manage conditions related to the renin‑angiotensin system.

- Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Cardiovascular risk management: contributes to lowering the incidence of stroke and myocardial infarction associated with uncontrolled high blood pressure. - Renal protection in hypertensive patients: helps slow the progression of kidney damage caused by sustained elevated blood pressure.

Olmesartán Vir may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Back pain - Elevated serum potassium

Serious or Rare Side Effects: - Angioedema, including swelling of the face, lips, tongue, or throat - Severe hypotension leading to fainting or shock - Acute kidney injury or worsening renal function - Hyperkalemia with potentially life‑threatening cardiac effects - Hepatic injury presenting as jaundice or elevated liver enzymes

When prescribing Olmesartán Vir, clinicians should observe several precautionary measures to ensure patient safety.

- Blood pressure monitoring: check baseline and periodic readings to assess therapeutic response. - Renal function assessment: evaluate serum creatinine and eGFR before initiation and during treatment. - Serum potassium measurement: monitor for hyperkalemia, especially in patients on potassium‑sparing agents. - Pregnancy avoidance: discontinue therapy in women who become pregnant and advise effective contraception. - Elderly dosing consideration: start at lower doses and monitor for orthostatic hypotension. - Store at ambient temperature: keep the tablets in the original container, protect from moisture and light.

Olmesartán Vir can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in patients with diabetes or renal impairment: increased risk of hypotension, hyperkalemia, and renal dysfunction. - Combined therapy with ACE inhibitors or other ARBs: may cause additive hyperkalemia and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone) or supplements: heightened risk of severe hyperkalemia. - NSAIDs (e.g., ibuprofen) in high‑risk patients: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: ARBs can increase lithium levels, requiring serum monitoring. - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise olmesartan concentrations. - Other antihypertensives (e.g., beta‑blockers, diuretics): additive blood pressure‑lowering effect, monitor for hypotension. - Diuretics causing volume depletion: may enhance renal effects of olmesartan.